Related Experiment Video
Updated: Aug 20, 2026
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens
Leonie C van Dinten1, Nicolien Pul, A Frans van Nieuwpoort
1Department of Immunohematology and Blood Transfusion, Division of Molecular Biology, Leiden University Medical Center, Leiden, The Netherlands.
Purpose:
Downregulation of melanoma-associated antigens (MAAs), against which natural cytolytic T lymphocytes (CTLs) exist in humans, is one of the mechanisms that aids in evasion of immune surveillance. In view of putative re-expression strategies for MAAs during immunotherapy, this study was conducted to investigate MAA silencing in malignant melanoma.
Methods:
The expression of the MAA Melan-A/MART-1 was analyzed in 10 uveal and 10 cutaneous patient-derived melanoma cell lines by Western blot analysis and RT-PCR. Expression characteristics of four other MAAs-Tyr, Tyrp1, Dct, and gp100/Pmel17-were analyzed by RT-PCR. DNA methylation patterns at the Melan-A/MART-1 promoter region were investigated by methylation-sensitive restriction enzyme digestion and subsequent Southern blot analysis. Exogenous promoter activity was assessed in all 20 melanoma cell lines to correlate the DNA methylation patterns with Melan-A/MART-1 expression.
Results:
MAA expression was observed in 15 of the 20 melanoma cell lines. Furthermore, there is a direct correlation between DNA methylation patterns at the Melan-A/MART-1 promoter region, exogenous Melan-A/MART-1 promoter activity, and Melan-A/MART-1 protein expression. These data reveal the division of patient-derived melanoma cell lines into two distinct subsets, which are identical for both uveal and cutaneous tumor types.
Conclusions:
The authors propose a categorization of melanoma cell lines into two different panels based on shared MAA-expression characteristics: panel I, MAA-expressing cell lines, and panel II, MAA-deficient cell lines. This categorization can be used to obtain knowledge about the regulation of MAA-expression and for further research concerning MAA-based immunotherapy.
Insights
Melanoma cells can evade immune surveillance by downregulating melanoma-associated antigens (MAAs). This study categorizes melanoma cell lines based on MAA expression, aiding immunotherapy research.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Melanoma-associated antigens (MAAs) are crucial targets for natural cytolytic T lymphocytes (CTLs).
- Downregulation of MAAs is a key mechanism by which malignant melanoma evades immune surveillance.
- Understanding MAA expression is vital for developing effective cancer immunotherapies.
Purpose of the Study:
- To investigate the silencing mechanisms of MAAs in malignant melanoma.
- To analyze MAA expression patterns in patient-derived melanoma cell lines.
- To explore the potential for MAA re-expression strategies in melanoma immunotherapy.
Main Methods:
- Analyzed Melan-A/MART-1 expression using Western blot and RT-PCR in 20 melanoma cell lines.
- Assessed expression of other MAAs (Tyr, Tyrp1, Dct, gp100/Pmel17) via RT-PCR.
- Investigated DNA methylation at the Melan-A/MART-1 promoter and correlated it with promoter activity and protein expression.
Main Results:
- Melanoma-associated antigen (MAA) expression was detected in 15 out of 20 cell lines.
- A direct correlation was found between DNA methylation, promoter activity, and Melan-A/MART-1 protein levels.
- Patient-derived melanoma cell lines were divided into two distinct subsets based on MAA expression, applicable to both uveal and cutaneous melanoma.
Conclusions:
- Proposed a categorization of melanoma cell lines into MAA-expressing (panel I) and MAA-deficient (panel II) groups.
- This classification aids in understanding MAA expression regulation.
- Facilitates further research into MAA-based immunotherapy strategies for melanoma.
